Zimmer Biomet Holdings, Inc. (ZBH) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Zimmer Biomet’s revenue went from $7.7B in fiscal 2016 to $8.2B in fiscal 2025, growth of about 0.8% a year.
Net income in fiscal 2025 was $705M, a net margin of 8.6%; the best year in this period was 2017 with $1.8B.
Over the twelve months to September 30, 2026, revenue was $8.6B and net income $767M.
Free cash flow was $1.5B in fiscal 2025 and positive in 10 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.6B | $8.2B | $7.7B | $7.4B | $6.9B | $6.8B | $6.1B | $8.0B | $7.9B | $7.8B | $7.7B |
| Gross profit | $6.0B | $5.7B | $5.5B | $5.3B | $4.9B | $4.9B | $4.3B | $5.7B | $5.7B | $5.7B | $5.3B |
| Operating income | $1.2B | $1.1B | $1.3B | $1.3B | $696M | $860M | $83M | $1.1B | $34M | $799M | $821M |
| Net income | $767M | $705M | $904M | $1.0B | $231M | $402M | -$139M | $1.1B | -$379M | $1.8B | $306M |
| EPS (diluted) | $3.96 | $3.55 | $4.43 | $4.88 | $1.10 | $1.91 | $-0.67 | $5.47 | $-1.86 | $8.90 | $1.51 |
| R&D | $433M | $458M | $437M | $459M | $406M | $436M | $323M | $449M | $392M | $370M | $366M |
| Revenue growth | — | +7.2% | +3.9% | +6.6% | +1.7% | +11.4% | −23.2% | +0.6% | +1.7% | +1.8% | +27.9% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.9B | $1.7B | $1.5B | $1.6B | $1.4B | $1.5B | $1.2B | $1.6B | $1.7B | $1.6B | $1.6B |
| Capital spending | -$241M | -$224M | -$204M | -$291M | -$188M | -$144M | -$112M | -$207M | -$163M | -$156M | -$185M |
| Free cash flow | $1.6B | $1.5B | $1.3B | $1.3B | $1.2B | $1.4B | $1.1B | $1.4B | $1.6B | $1.4B | $1.4B |
| Dividends paid | $187M | $190M | $196M | $201M | $201M | $200M | $198M | $197M | $195M | $194M | $188M |
| Buybacks | $829M | $487M | $868M | $692M | $126M | — | — | — | — | — | $416M |
| Stock-based pay | $97M | $90M | $101M | $100M | $105M | $76M | $74M | $84M | $66M | $54M | $57M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $592M | $526M | $416M | $376M | $378M | $802M | $618M | $543M | $524M | $634M |
| Debt | — | $7.8B | $6.4B | $6.0B | $5.9B | $7.4B | $8.4B | $8.5B | $9.2B | $10.1B | $11.2B |
| Equity | — | $12.7B | $12.5B | $12.5B | $12.0B | $12.7B | $12.2B | $12.4B | $11.3B | $11.7B | $9.7B |
| Total assets | — | $23.1B | $21.4B | $21.5B | $21.1B | $23.5B | $24.4B | $24.6B | $24.1B | $26.0B | $26.7B |
| Shares (diluted) | 191M | 199M | 204M | 210M | 210M | 210M | 207M | 207M | 204M | 204M | 202M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 69.7% | 69.7% | 71.5% | 71.8% | 70.9% | 71.3% | 70.2% | 71.8% | 71.4% | 72.7% | 68.9% |
| Operating margin | 13.6% | 13.3% | 16.7% | 17.3% | 10.0% | 12.6% | 1.4% | 14.2% | 0.4% | 10.2% | 10.7% |
| Net margin | 9.0% | 8.6% | 11.8% | 13.9% | 3.3% | 5.9% | -2.3% | 14.2% | -4.8% | 23.2% | 4.0% |
| FCF margin | 19.2% | 17.9% | 16.9% | 17.4% | 16.8% | 19.9% | 17.8% | 17.3% | 20.0% | 18.3% | 18.9% |
| ROIC | — | 4.6% | 5.9% | 6.6% | 2.8% | 3.8% | 0.3% | 4.3% | 0.1% | 2.9% | 3.0% |
| ROE | — | 5.5% | 7.2% | 8.2% | 1.9% | 3.2% | -1.1% | 9.1% | -3.4% | 15.5% | 3.2% |
Frequently asked questions
What is Zimmer Biomet’s annual revenue?
$8.2B in fiscal 2025 and $8.6B over the twelve months to September 30, 2026.
How much profit does Zimmer Biomet make?
Net income was $705M in fiscal 2025 (net margin 8.6%).
Is Zimmer Biomet’s revenue growing?
Yes: revenue rose 7.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.